从China供应商批量进口5-Azacytidine

5-azacytidine, CAS 320-67-2, is a nucleoside analogue used to inhibit DNA methyltransferase, thereby altering gene expression patterns in mammalian cells. The listing describes it as suitable for epigenetic research, pharmaceutical development, and clinical trial applications, though no specific purity percentage, assay method, or certificate of analysis details are provided in the source data. Buyers should request the exact batch-specific purity, typically expressed as HPLC area percent, and the residual solvent profile before purchase.

This compound is hygroscopic and sensitive to light and temperature, requiring storage under controlled conditions to prevent degradation to 5-fluorocytosine or other breakdown products. The supplier states availability in bulk supply, but does not define pack sizes, container types, or inert gas flushing. Standard industry practice for such API-grade chemicals includes double-sealed aluminium-laminated bags with desiccant, or amber glass vials with argon headspace; confirm with Jinan Mingrui which configuration they provide and whether the packaging is certified for international air freight.

Typical purchasers include biotechnology firms running high-throughput screening, academic laboratories studying demethylation kinetics, and pharmaceutical manufacturers formulating investigational drugs. The supplier mentions compliance with international standards and provision of safety data sheets, but does not name specific pharmacopoeial references such as USP, EP, or CP monographs. Importers should verify GMP status, DMF availability, and whether the manufacturing site has been audited by any regulatory authority, as these factors determine suitability for clinical versus research-only use.

Jinan Mingrui Medical Technology Co., Ltd is located at Kaiyuan Road, Licheng District, Jinan, 250101, Shandong Province, China. The supplier holds an Imported tier designation alongside a Harbor trust tier, which indicates some level of platform recognition but does not substitute for buyer-conducted due diligence. The response rate is 0.00 percent and average response hours are zero, so direct communication may be slow and buyers should consider follow-up by telephone or through an agent.

The company name suggests a medical technology orientation, yet the listing provides no information about manufacturing site GMP certification, QC laboratory accreditation, or regulatory filing history. Year of establishment, number of employees, and annual turnover are not disclosed. The source description contains generic marketing language that buyers should treat cautiously; all technical and compliance claims need independent verification through documentation requests and, where feasible, third-party audit.